Dimensional Fund Advisors LP Sells 14,775 Shares of Edwards Lifesciences Co. (NYSE:EW)

Posted by Defense World Staff on May 25th, 2023

Dimensional Fund Advisors LP decreased its stake in Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 1.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,089,661 shares of the medical research company’s stock after selling 14,775 shares during the period. Dimensional Fund Advisors LP owned about 0.18% of Edwards Lifesciences worth $81,303,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in EW. Trifecta Capital Advisors LLC purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $28,000. Addison Advisors LLC boosted its position in Edwards Lifesciences by 708.0% during the 4th quarter. Addison Advisors LLC now owns 404 shares of the medical research company’s stock valued at $30,000 after buying an additional 354 shares during the period. New England Capital Financial Advisors LLC purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $42,000. WASHINGTON TRUST Co boosted its position in Edwards Lifesciences by 252.5% during the 4th quarter. WASHINGTON TRUST Co now owns 698 shares of the medical research company’s stock valued at $52,000 after buying an additional 500 shares during the period. Finally, RFP Financial Group LLC purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $53,000. Institutional investors own 80.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Piper Sandler increased their price target on shares of Edwards Lifesciences from $80.00 to $83.00 in a research report on Thursday, April 27th. Mizuho raised their target price on shares of Edwards Lifesciences from $85.00 to $95.00 in a research report on Tuesday, April 25th. Canaccord Genuity Group raised their target price on shares of Edwards Lifesciences from $68.00 to $76.00 and gave the stock a “hold” rating in a research report on Wednesday, February 1st. 92 Resources reaffirmed a “reiterates” rating on shares of Edwards Lifesciences in a research report on Thursday, May 4th. Finally, Sanford C. Bernstein lowered shares of Edwards Lifesciences from an “outperform” rating to an “underperform” rating and decreased their price target for the stock from $95.00 to $66.00 in a research note on Tuesday, January 31st. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $89.63.

Insider Activity at Edwards Lifesciences

In related news, VP Jean-Luc M. Lemercier sold 6,640 shares of the business’s stock in a transaction that occurred on Wednesday, March 8th. The shares were sold at an average price of $76.96, for a total transaction of $511,014.40. Following the completion of the sale, the vice president now directly owns 168,875 shares in the company, valued at $12,996,620. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 19,875 shares of the company’s stock in a transaction that occurred on Tuesday, March 14th. The shares were sold at an average price of $77.61, for a total value of $1,542,498.75. Following the completion of the transaction, the chief executive officer now directly owns 60,948 shares in the company, valued at $4,730,174.28. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Jean-Luc M. Lemercier sold 6,640 shares of the company’s stock in a transaction that occurred on Wednesday, March 8th. The stock was sold at an average price of $76.96, for a total transaction of $511,014.40. Following the completion of the transaction, the vice president now owns 168,875 shares of the company’s stock, valued at $12,996,620. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 189,091 shares of company stock worth $16,232,258. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Down 1.1 %

EW opened at $83.84 on Thursday. The company has a quick ratio of 2.17, a current ratio of 3.01 and a debt-to-equity ratio of 0.10. The firm has a 50 day moving average price of $85.10 and a 200-day moving average price of $79.40. Edwards Lifesciences Co. has a twelve month low of $67.13 and a twelve month high of $107.92. The stock has a market capitalization of $50.83 billion, a price-to-earnings ratio of 34.79, a PEG ratio of 5.07 and a beta of 1.02.

Edwards Lifesciences (NYSE:EW – Get Rating) last released its quarterly earnings data on Wednesday, April 26th. The medical research company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.01. Edwards Lifesciences had a net margin of 27.07% and a return on equity of 25.81%. The firm had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.39 billion. During the same period in the previous year, the company earned $0.60 earnings per share. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.55 earnings per share for the current year.

About Edwards Lifesciences

(Get Rating)

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.